IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
420 em ploy ees (in clud ing its four 100% sub sid iar ies). The new ven ture is ex pect ing con sol i dated sales of
around Yen36 bil lion. The ar range ment was ap proved by both Jap a nese reg u la tors and the EC, on the ba -
sis that Takeda’s busi ness was largely domestic and Sumitomo’s was largely international.
Takeda an nounced plans to sell its 32.5% hold ing in Shimizu Seiyaku to Suzuyo (Ja pan). Takeda will end
its sales con tract with Shimizu Seiyaku at the end of March 2003. The moves fol low an agree ment by Aji -
no mo to to ac quire Shimizu Seiyaku and its wholly-owned sub sid iary Shimizu Med i cal by the end of 2002.
Takeda was re quired to pay Yen500 mil lion in pen alty taxes fol low ing in cor rect book ing of in come and ex -
penses dur ing 2000 and 2001.
A for mer TAP sales rep re sen ta tive pleaded guilty to a charge of vi o lat ing the US pre scrip tion Drug Mar ket -
ing Act in re spect of Lupron (leuprorelin). The rep re sen ta tive had failed to ob tain a writ ten re quest from a
phy si cian for free sam ples, and could face a jail sen tence plus a $100,000 fine. By July 2002, 14 TAP em -
ploy ees in clud ing three se nior ex ec u tives had been charged since the start of the Fed eral in ves ti ga tion
into Lupron-related fraud.
TPNA (Takeda Pharmaceuticals North Amer ica) re struc tured its se nior ex ec u tive team and ap pointed a
new Pres i dent, Mark Booth, to take man age ment re spon si bil ity for all TPNA’s business.
Con tracts be tween Takeda and Ad vance PCS, a US phar macy ben e fit man age ment com pany, be came
the sub ject of an in ves ti ga tion by the Phil a del phia US At tor ney’s Of fice in ves ti gat ing whether Ad vance
PCS prop erly re ported re bates to Fed eral Em ployee Health Ben e fit pro grams. Takeda is one of 14 man u -
fac tur ers whose contracts are being examined.
Takeda an nounced it is to sell its syn thetic rub ber la tex busi ness to Nip pon AL, a jv be tween Sumitomo
Chem i cal (Ja pan) and Mitsui Chem i cals (Ja pan). For mal trans fer was due in October 2002.
TAP ex plained that it was not the tar get of an in ves ti ga tion that re sulted in sev eral US health ben e fit man -
age ment com pa nies re ceiv ing re ceived Fed eral sub poe nas in April and May 2002. Some of the com pa nies
were asked for doc u ments re lat ing to their relationship with TAP.
TAP’s Phar ma ceu ti cal Eth ics and Com pli ance Of fi cer agreed to chair the US Health Care Com pli ance As so -
ci a tion task force to de velop mea sure ments to eval u ate the ef fec tive ness of cor po rate com pli ance pro -
grams. As part of its set tle ment of crim i nal and civil charges re lated to Lupron pro mo tion, TAP agreed to
an ex ten sive corporate integrity program
Takeda an nounced plans to in vest around Euro80 mil lion in a new bulk phar ma ceu ti cal pro duc tion plant
in Clondalkin, Ire land. It will be Takeda’s first such fa cil ity out side Ja pan. Op er a tions are sched uled to be -
gin in 2004, when the plant will ini tially pro duce Actos (pioglitazone) for Eu ro pean and US mar kets and
new com pounds for clin i cal tri als. Takeda al ready has a for mu la tion and pack ag ing plant in Ire land. The
two sites will be run as sep a rate com pa nies, with the new bulk plant tak ing over the Takeda Ire land
name. The ex ist ing pack ag ing and for mu la tion site will be renamed Takeda Ireland Products.
• Year: 2001
The Jap a nese Phar ma ceu ti cal Group (JPG), was set up in the UK to rep re sent the views of 10 R&D Jap a -
nese com pa nies, in clud ing Takeda, which sell branded med i cines to the NHS.
Takeda an nounced its in ten tion to es tab lish an in vest ment com pany in the USA, called Takeda Re search
In vest ment (TRI) on the west coast, which will pro vide fund ing for bio tech nol ogy start-ups and
early-stage ven tures con duct ing re search or de vel op ing tech nol o gies for in no va tive drug dis cov ery. TRI
was given an in vest ment fund of $100 mil lion and will take stakes in tar get com pa nies to ac cel er ate
Takeda’s own re search activities in the area by 2005.
© 2009 IMS Health In cor po rated or its af fil i ates Page 115